Shareholders Approve Strategic Sale of Latin American Assets to Aphria in Exchange for 15,678,310
shares of Aphria (TSX:APH)
Shareholders Approve Name Change to SOL Investments Corp.
Scythian’s Issued and Outstanding Shares Expected to be 48,849,218 Post-Closing of the
Transaction
TORONTO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or
“Scythian”) (CSE:SCYB) (Frankfurt:9SB) (OTC – Nasdaq Intl: SCCYF) is pleased to announce the results of Scythian’s
special meeting of shareholders on September 14, 2018 (“Special Meeting”).
At the Special Meeting, shareholders approved the sale of the Company’s South American and Caribbean assets to
Aphria Inc. (TSX: APH) (the “Transaction”), the terms and conditions of which were set out in the Company’s
management information circular dated August 13, 2018. The Transaction required the approval of a simple majority of the
shareholders and, because Aphria is a “related party” to Scythian under applicable securities law, also required the approval of
the majority of the minority shareholders in accordance with Multilateral Instrument 61-101 – Protection of Minority Security
Holders in Special Transactions. The detailed results of the majority of the minority vote were as follows:
|
Special Matter |
Total Votes |
Votes For |
% Votes For |
Votes Against |
% Votes Against |
|
Approval of the Transaction |
10,295,949 |
10,272,914 |
99.8% |
23,035 |
0.2% |
The closing of the Transaction is expected to occur on or about the end of September, 2018.
Scythian’s shareholders also approved a special resolution authorizing the amendment of the Company’s articles
to change the name of the Corporation from “Scythian Biosciences Corp.” to “SOL Investments Corp.” (the “Name
Change”). The Name Change will take effect following the completion of the Transaction.
On September 14, 2018, the Company announced the entering into of a share purchase agreement with MMJ
International Investments Inc. (“MMJ”) and all of the shareholders of MMJ. MMJ owns ABP S.A., an Argentinean
pharmaceutical distribution company. If completed, and after giving effect to the recently completed acquisitions of MMJ Colombia
Partners Inc. and Marigold Acquisitions Inc. the number of issued and outstanding common shares of the Company is expected to be
48,849,218.
About Scythian Biosciences Corp.
Scythian is an international cannabis company with a focus on legal U.S. states. Its strategic investments and
partnerships across cultivation, distribution and retail complement the company’s R&D program with the University of Miami. It
is this comprehensive approach that is positioning Scythian as a future frontrunner in the United States’ medical cannabis
industry.
CONTACT INFORMATION
Scythian Biosciences Corp.
Rob Reid, CEO
Phone: (212) 729-9208
Email: info@scythianbio.com
For media inquiries, please contact:
David Schull or Nic Johnson
Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
nic.johnson@russopartnersllc.com
Cautionary Statements
This press release contains certain forward-looking information and statements (“forward-looking
information”) within the meaning of applicable Canadian securities legislation, that are not based on historical fact,
including without limitation, statements containing the words "believes", "anticipates", "plans", "intends", "will", "should",
"expects", "continue", "estimate", "forecasts" and other similar expressions. Such forward-looking information includes information
relating to the completion of the Transaction, the Name Change and the number of issued and outstanding common shares of the
Company.
Readers are cautioned to not place undue reliance on forward-looking information. Forward-looking
information is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from
those contemplated in the forward-looking information, and even if such actual results or events are realized or substantially
realized, there can be no assurance that they will have the expected consequences to, or effects on the Company. Such risks and
uncertainties include, among other things, the risk that a condition to the completion of the Transaction may not be satisfied or
that a regulatory or stock exchange approval that may be required for the Transaction is not obtained or is obtained subject to
conditions that are not anticipated.
Other risks and uncertainties include but are not limited to: the Company’s ability to comply with all
applicable governmental regulations in a highly regulated business; investing in target companies or projects which have limited or
no operating history and are engaged in activities currently considered illegal under US federal laws; changes in laws; limited
operating history; competition; reliance on management; requirements for additional financing; competition; inconsistent public
opinion and perception regarding the medical-use and adult-use marijuana industry and; regulatory or political change. Risk factors
can also be found in the Company’s annual information form filed on SEDAR and available at www.sedar.com.
The forward-looking information contained in this press release are expressly qualified by this cautionary
statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except
as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or
otherwise.
